Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Single-Arm, Phase II Study to Explore the Efficacy and Safety of MEK1/2 Inhibitor (MEKi) Selumetinib in the Treatment of Patients With NF2-Related Schwannomatosis

NCT07707947 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT07707947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07707947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Single-Arm, Phase II Study to Explore the Efficacy and Safety of MEK1/2 Inhibitor (MEKi) Selumetinib in the Treatment of Patients With NF2-Related Schwannomatosis
Lead sponsor
Beijing Tiantan Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 15, 2026
Completion date
December 31, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ependymoma, meningioma, neurofibromatosis type 2, nf2, nf2-related schwannomatosis, vestibular schwannoma